Anti–vascular Endothelial Growth Factor Therapy Market
Anti–vascular Endothelial Growth Factor Therapy
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Anti–vascular Endothelial Growth Factor Therapy
Market Size and Growth
The Anti-vascular Endothelial Growth Factor Therapy market research reports highlight a growing demand for innovative therapies targeting vascular endothelial growth factor. The market size is expected to reach USD 11.3 billion by 2025, driven by increasing prevalence of diseases such as cancer, macular degeneration, and diabetic retinopathy. Emerging biotech companies are also contributing to market growth.
Request Sample Report
Companies Covered (Covid 19 Impact Covered)
◍ Regeneron Pharmaceuticals (Eylea)
◍ Genentech
◍ Kanghong Pharmaceutical
Competitive Landscape: The Anti–vascular Endothelial Growth Factor Therapy Market is dominated by key players such as Regeneron Pharmaceuticals with Eylea, Genentech, and Kanghong Pharmaceutical. These companies offer innovative treatments for eye diseases like wet AMD and diabetic retinopathy, driving market growth through their advanced therapies.
Sales revenue:
- Regeneron Pharmaceuticals: $5.3 billion
- Genentech: $3.3 billion
- Kanghong Pharmaceutical: $1.7 billion
Request Sample Report
Market Segmentation
By Application
◍ Macular Degeneration
◍ Nacular Edema
◍ Uveitis
◍ Retinal Vein Occlusion
By Product
◍ Extraction Injection ◍ Precharge Injection
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
